Veracyte (VCYT) Soars 7.0%: Is Further Upside Left in the Stock?

Veracyte VCYT shares rallied 7% in the last trading session to close at $25.25. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 12% loss over the past four weeks.Veracyte recorded a strong price rise on investors’ optimism surrounding its impending second-quarter 2025 financial results, which is slated to be released on Aug. 6, 2025, post the closing bell. Per the Zacks Consensus Estimate, the company’s second quarter revenue and earnings per share (EPS) suggests an improvement of 6.2% and 3.3%, respectively. This molecular diagnostic company is expected to post quarterly earnings of $0.31 per share in its upcoming report, which represents a year-over-year change of +3.3%. Revenues are expected to be $121.58 million, up 6.3% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For Veracyte, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on VCYT going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Veracyte is part of the Zacks Medical - Instruments industry. TransMedics TMDX, another stock in the same industry, closed the last trading session 1.3% higher at $108.12. TMDX has returned -17.9% in the past month.For TransMedics, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.48. This represents a change of +37.1% from what the company reported a year ago. TransMedics currently has a Zacks Rank of #3 (Hold).5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They includeStock #1: A Disruptive Force with Notable Growth and ResilienceStock #2: Bullish Signs Signaling to Buy the DipStock #3: One of the Most Compelling Investments in the MarketStock #4: Leader In a Red-Hot Industry Poised for GrowthStock #5: Modern Omni-Channel Platform Coiled to SpringMost of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Veracyte, Inc. (VCYT): Free Stock Analysis Report TransMedics Group, Inc. (TMDX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks